Participants in research

BMJ 2005; 330 doi: 10.1136/bmj.330.7501.1164 (Published 19 May 2005)
Cite this as: BMJ 2005;330:1164

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. David L Sackett, director (sackett@bmts.com)
  1. Trout Research and Education Centre at Irish Lake, RR 1, Markdale, ON, Canada N0C 1H0

    Neither guinea pigs nor sacrificial lambs, but pointers to better health care

    Patients rightly worry that they risk being sacrificed in randomised trials whose results cannot be applied by clinicians in the front lines of real clinical practice. In a recent US survey, half the public considered trial participants to be “guinea pigs.” Altruistic goals such as “making a contribution to science” were judged far more likely to be achieved than personal benefits such as “getting the best possible treatment” or “having access to the best physician.”1 At the same time, many clinicians worry that the imposition of rigorous trial conditions on highly selected patients, especially in tertiary care settings, generates results that cannot be generalised to routine clinical practice.2

    For the most part, these concerns originated from, and are perpetuated by, the examination of single trials or highly selective collections of them. Reports of the ghastly abuse of trial participants are sufficiently frequent and well publicised that they cause some to question …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL